FDA Grants Orphan Drug Designation to ATXA’s NTP42 for the Treatment of PAH
DUBLIN, IRELAND – March 8, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical development of novel small molecule drugs to treat Pulmonary Arterial Hypertension (PAH), is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ATXA's lead clinical candidate NTP42 for the treatment of PAH. The company received written notification of this rapid decision from the FDA o